NCT06941662 Huntington's Disease Biobank: Advancing Remote Monitoring and Deep Phenotyping
| NCT ID | NCT06941662 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Stanford University |
| Condition | Huntington Disease |
| Study Type | OBSERVATIONAL |
| Enrollment | 200 participants |
| Start Date | 2024-06-01 |
| Primary Completion | 2035-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 200 participants in total. It began in 2024-06-01 with a primary completion date of 2035-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This observational study aims to identify novel biomarkers of disease onset and progression in Huntington's disease by integrating remote monitoring with fluid biomarkers. Using video-based computer vision and mobile app-based cognitive assessments combined with machine learning algorithms, we aim to develop markers that can be used by Huntington's disease patients at home. Using machine learning to analyze videos of movement will capture the movements with an accuracy that will be as good as seeing an expert neurologist. These individualized markers can be followed over time to evaluate symptoms onset and change. The study will track disease progression and correlate these digital markers with changes in plasma and cerebrospinal fluid. The ultimate goal is to advance biomarker discovery and therapeutic development for Huntington's disease. The study includes one in-person visit per year. A remote visit via Zoom or Facetime (15 min) every three months to record videos of movement. We can also share cutting-edge wristbands and a mobile phone app.
Eligibility Criteria
Inclusion Criteria: * Individuals with a positive test for the HD expansion mutation. Exclusion Criteria: * Individuals with movement disorders with a negative test for the HD expansion mutation.
Contact & Investigator
Kyan Younes, MD
PRINCIPAL INVESTIGATOR
Stanford University
Frequently Asked Questions
Who can join the NCT06941662 clinical trial?
This trial is open to participants of all sexes, studying Huntington Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06941662 currently recruiting?
Yes, NCT06941662 is actively recruiting participants. Contact the research team at mtchu@stanford.edu for enrollment information.
Where is the NCT06941662 trial being conducted?
This trial is being conducted at Palo Alto, United States.
Who is sponsoring the NCT06941662 clinical trial?
NCT06941662 is sponsored by Stanford University. The principal investigator is Kyan Younes, MD at Stanford University. The trial plans to enroll 200 participants.